Key Details and Chronology

This disclosure is in continuation of earlier company intimations dated August 6, 2026, and May 2, 2026. The subject US FDA inspection was conducted at the Amaliya, Daman facility from April 20, 2026, to May 1, 2026. Following that inspection, the US FDA had classified the facility's status as Official Action Indicated (OAI).

The company has now received a warning letter from the US FDA dated November 18, 2026, pertaining to the same inspection. The letter was received on November 18, 2026.

Details of the Action

The warning letter is based on observations made by the USFDA during the April 2026 inspection. It requires the company to implement appropriate corrective and preventive actions to address the observations and prevent their recurrence.

The company states it shall be responding to the US FDA within the stipulated timeline provided by the regulator.

Operational and Financial Impact

As per the disclosure, the company states unequivocally that "There is no material impact on current operation, financial or other activities of the Company."

The company also confirms that it continues to manufacture and supply approved products from the Amaliya, Daman facility to the U.S. market.

Filing and Compliance Details

  • Disclosure Date: November 19, 2026